Role of cannabinoid receptors in bone disorders: Alternatives for treatment

Drug News and Perspectives

Volumn 21, Issue 10, 2008, Pages 533-540

  Idris, Aymen I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; ANANDAMIDE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; RIMONABANT; UNCLASSIFIED DRUG;

BONE CELL; BONE DISEASE; BONE MASS; BONE METASTASIS; BONE REMODELING; CELL FUNCTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DENSITY; BONE DISEASES; BONE NEOPLASMS; CANNABINOIDS; HUMANS; OSTEOPOROSIS; RECEPTORS, CANNABINOID;

EID: 62649160576     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.10.1314055     Document Type: Review

References (101)

1. Klein, T.W., Lane, B., Newton, C.A. and Friedman, H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000, 225(I): 1-8.
2. Grant, I. and Cahn,B.R. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin Neurosci Res 2005, 5(2-4): 185-99.
3. Di, M.V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008, 7: 438-55.
4. Pertwee, R.G. and Ross, R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002, 66(2-3): 101-21.
5. Maccarrone, M. and Finazzi-Agrò, A. Endocannabinoids and their actions. Vitam Horm 2002, 65: 225-55.
6. Ryberg, E., Larsson, N., Sjögren, S. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152(7): 1092-101.
7. Begg, M., Pacher, P., Bátkai, S. et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005, 106(2): 133-45.
8. Bouaboula, M., Rinaldi, M., Carayon, P. et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993, 214(1): 173-80.
9. Klein, T.W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L. and Friedman, H. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74(4): 486-96.
10. Ofek, O., Karsak, M., Leclerc, N. et al. Peripheral cannabinoid receptor CB2, regulates bone mass. Proc Natl Acad Sci USA 2006, 103(3): 696-701.
11. Idris, A.I., van 't Hof, R.J., Greig, I.R., Ridge, S.A., Baker, D., Ross, R.A., and Ralston, S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11(7): 774-9.
12. Pertwee, R.G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005, 168: 1-51.
13. Ross, R.A., Brockie, H.C., Stevenson, L.A., Murphy, V.L., Templeton, F., Makriyannis, A. and Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 1999, 126(3): 665-72.
14. Bouaboula, M. Poinot-Chazel, C., Marchand, J. et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996, 237(3): 704-11.
15. Sanchez, M.G., Ruiz-Llorente, L., Sanchez, A.M. and Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(7) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 2003, 15(9): 851-9.
16. Guzman, M., Galve-Roperh, I. and Sanchez, C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 2001, 22(1): 19-22.
17. Guzman, M., Sanchez, C. and Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001, 78(11): 613-25.
18. Molina-Holgado, E., Vela, J.M., Arévalo-Martín, A., Almazán, G., Molina-Holgado, F., Borrell, J. and Guaza, C. et al. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002, 22(22): 9742-53.
19. Ho, B.Y., Current, L. and Drewett, J.G. Role of intracellular loops of cannabinoid CB(1) receptor in junctional interaction with G(alpha16). FEBS Lett 2002, 522(1-3): 130-4.
20. Daaka, Y., Zhu, W., Friedman, H. and Klein, T.W. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor DNA Cell Biol 1997, 16(3): 301-9.
21. Bouaboula, M., Dussossoy, D. and Casellas, P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 1999, 274(29): 20397-405.
22. Bouaboula, M., Perrachon, S. Milligan, L. et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor I. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997, 272(35): 22330-9.
23. Ducy, P., Schinke, T. and Karsenty, G. The osteoblast: A sophisticated fibroblast under central surveillance. Science 2000, 289(5484): 1501-4.
24. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 2000, 289(5484): 1504-8.
25. Amling, M., Pagoda, P., Beil, F.T. et al. Central control of bone mass: brainstorming of the skeleton. Adv Exp Med Biol 2001, 496: 85-94.
26. Takeda, S., Elefteriou, F., Levasseur, R. et al Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111(3): 305-17.
27. Elefteriou, F. Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 2005, 62(19-20): 2339-49.
28. Chenu, C. Glutamatergic innervation in bone. Microsc Res Tech 2002, 58(52): 70-6.
29. Armour, K.E., Armour, K.J., Gallagher, M.E., Gödecke, A., Helfrich, M.H., Reid, D.M. and Ralston, S.H. Defective bone formation, and anabolic responses to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001, 142(2): 760-6.
30. Tam, J.,Ofek, O., Fride, E. et al. Involvement of neuronal cannabinoid receptor, GB1, in regulation of bone mass and bone remodeling. Mol Pharmacol 2006, 70(3): 786-92.
31. Idris, A.I., Sophocleous, A., Landao-Bassonga, E., Van't Hof R.J. and Ralston, S. Bidirectional regulation of peak bone mass and age-related bone loss by the type I cannabinoid receptor. Calcif Tissue Int 2008, 82(Suppl. 1): S57.
32. Pryce, G., Ahmed, Z., Hankey, D.J. et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126(Pt 10): 2191-202.
33. Nong, L., Newton, C., Friedman, H. and Klein, T. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. In: Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases. Friedman, H., Klein, T.W. and Madden, J. (Eds.). Kluwer Academic/Plenum Publishers: New York 2001, 223-8.
34. Galiegue, S., Mary, S., Marchand, J. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232(1): 54-61.
35. Scutt, A. and Williamson, E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 2007, 80(1): 50-9.
36. Palazuelos, J., Davoust, N., Julien, B. et al. The CB(2) cannabinoid receptors controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008, 283(19): 13320-9.
37. Ridge, S.A., Ford, L., Cameron, G.A., Ross, R.A. and Rogers, M.J. Endocannabinoids are produced by bone cells and stimulate bone resorption in vitro. Calcif Tissue Int 2007, Abst S120.
38. Idris, A.I., Sophocleous, A., Landao-Basonga, E., van't Hof, R.J. and Ralston, S.H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type of cannabinoid receptor. Endocrinology 2008, 149(11): 5619-26.
39. Sophocleous, A., Landao-Bassonga, E., Van't Hof, R.J., Idris, A.I. and Ralston, S. Cannabinoid receptor 2 selective agonists stimulate osteoclast formation in vitro but act as anabolic agents in vivo by stimulating bone formation. Calcif Tissue Int 2008, 82(Suppl. 1): S111.
40. Scutt, A. and Williamson, E.M. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 2007, 80(1): 50-9.
41. Tam, J., Trembovler, V., Di Marzo, V. et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008, 22(1): 285-94.
42. Bab, I. and Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 2008, 153(2): 182-8.
43. Ahlborg, H.G. Johnell, O., Turner, C.H., Rannevik, G. and Karlsson, M.K. Bone loss and bone size after menopause. N Engl J Med 2003, 349(4): 327-34.
44. Eastell, R. Treatment of Post menopausal osteoporosis [see comments]. N Engl J Med 1998, 338(11): 736-46.
45. Rodan, G.A. and Martin, T.J. Therapeutic approaches to bone diseases. Science 2000, 289(5484): 1508-14.
46. Reid, I.R. and Grey, A.B. Bailliere's Clinical Rheumatology. Reid, D.M. (Ed.), (Bailliere Tindall, London) 1993, 573-87.
47. Lafage-Proust, M.H., Boudignon, B. and Thomas, T. Glucocorticoid-induced osteoporosis: Pathophysiological data and recent treatments. Joint Bone Spine 2003, 70(2): 109-18.
48. Di Marzo, V. and Szallasi, A. Rimonabant in rats with a metabolic syndrome: Good news after the depression. Br J Pharmacol 2008, 154(5): 915-7.
49. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. and Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295(7): 761-75.
50. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D. and Van Gaal, L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548): 1660-72.
51. Karsak, M., Cohen-Solal, M., Freudenberg, J. et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005, 14(22): 3389-96.
52. Yamada, Y., Ando, F. and Shimokata, H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 2007, 19(5): 791-801.
53. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H. and Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370(9600): 1706-13.
54. Saville, P.D. and Kharmosh, O. Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids. Arth Rheum 1967, 10: 423-30.
55. Sweeney, S.E. and Firestein, G.S. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004, 36(3): 372-8.
56. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937): 356-61.
57. Sweeney, S.E. and Firestein, G.S. Rheumatoid arthritis: regulation of synovial inflammation, Int J Biochem Cell Biol 2004, 36(3): 372-8.
58. Feldmann, M., Brennan, F.M., Foxwell, B.M. and Maini, R.N. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001, 3: 188-99.
59. Lipsky, P.E., van der Heijde, D.M., St. Clair, E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343(22): 1594-602.
60. Feldmann, M., Brennan, F.M., Williams, R.O., Woody, J.N. and Maini, R.N. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004, 18(1): 59-80.
61. Zwerina, J., Hayer, S., Tohidast-Akrad, M. et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004, 50(1): 277-90.
62. Klein, T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5(5): 400-11.
63. Shohami, E., Gallily, R., Mechoulam, R., Bass, R. and Ben Hur, T. Cytokine production in the brain following closed head injury dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997, 72(2): 169-77.
64. Baldwin, G.C., Tashkin, D.P., Buckley, D.M., Park, A.N., Dubinett, S.M., and Roth, M,D. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997, 156(5): 1606-13.
65. Smith, S.R., Terminelli, C. and Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol Exp Ther 2000, 293(1): 136-50.
66. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. and Feldmann, M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000, 97(17): 9561-6.
67. Bidinger, B., Torres, R., Rossetti, R.G. et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 2003, 108(2): 95-102.
68. Dajani, E.Z., Larsen, K.R., Taylor, J. et al. 1′,1′-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: A novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Exp Ther 1999, 291(1): 31-8.
69. Maccarrone, M., De Petrocellis, L., Bari, M., Fezza, F., Salvati, S., Di Marzo, V. and Finazzi-Agrò, A. Lipopolysaccharide down-regulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001, 393(2): 321-8.
70. Di Marzo, V., De Petrocellis, L., Sepe, N. and Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 1996, 316(Pt. 3): 977-84.
71. Matias, I., Pochard, P., Orlando, P., Salzet, M., Pestel, J. and Di Marzo, V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002, 269(15): 3771-8.
72. Kishimoto, S., Kobayashi, Y., Oka, S., Gokoh, M., Waku, K. and Sugiura, T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem 2004, 135(4): 517-24.
73. Derocq, J.M., Jbilo, O., Bouaboula, M., Ségui, M., Clère, C. and Casellas, P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 2000, 275(21): 15621-8.
74. Lunn, C.A., Fine, J., Rojas-Triana, A. et al. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss. Immunopharmacol Immunotoxicol 2007, 29(3-4): 387-401.
75. Mundy, G.R. Mechanisms of bone metastasis. Cancer 1997, 80(8 Suppl.): 1546-56.
76. Roodman, G.D. Biology of osteoclast activation in cancer. J Clin Oncol 2001, 19(15): 3562-71.
77. Lipton, A. Future treatment of bone metastases. Clin Cancer Res 2006, 12(20 Pt. 2): 6305s-8s.
78. Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3): 165-76.
79. Mundy, G.R. Mechanisms of osteolytic bone destruction. Bone 1991, 12(Suppl. 1): S1-S6.
80. Roux, S., Meignin, V., Quillard, J. et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002, 117(1): 86-92.
81. Seidl, S., Kaufmann, H. and Drach, J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003, 4(9): 557-64
82. Siclari, V.A., Guise, T.A. and Chirgwin, J.M. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006, 25(4): 621-33.
83. Guzman, M. Cannabinoids: Potential anti-cancer agents. Nat Rev Cancer 2003, 3(10): 745-55.
84. Bifulco, M., Laezza, C., Pisanti, S. and Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006, 148(2): 123-35.
85. Bifulco, M., Malfitano, A.M., Pisanti, S. and Laezza, C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 2008, 15(2): 391-408.
86. Sarfaraz, S., Adhami, V.M., Syed, D.N., Afaq, F. and Mukhtar, H. Cannabinoids for cancer treatment progress and promise. Cancer Res 2008, 68(2): 339-42.
87. Di Marzo, V., Bifulco, M. and De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3(9): 771-84.
88. Bifulco, M., Laezza, C., Gazzerro, P. and Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncol Rep 2007, 17(4): 813-6.
89. Grimaldi, C., Pisanti, S., Laezza, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006, 312(4): 363-73.
90. Sarfaraz, S., Afaq, F., Adhami, V.M. and Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005, 65(5): 1635-41.
91. Islam, T.C., Asplund, A.C., Lindvall, J.M. et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 2003, 17(9): 1880-90.
92. Joosten, M., Valk, P.J., Jordà, M.A. et al. Leukemia predisposition of pSca-1/Cb2 transgenic mice. Exp Hematol 2002, 30(2): 142-9.
93. Velasco, L., Ruiz, L., Sanchez, M.G. and Diaz-Laviada, 1. delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 2001, 268(3): 531-5.
94. Ruiz, L., Miguel, A. and Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 1999, 458(3): 400-4.
95. Sarker, K.P., Obara, S., Nakata, M., Kitajima, I. and Maruyama, I. Anandamide induces apoptosis of PC-12 cells: Involvement of superoxide and caspase-3. FEBS Lett 2000, 472(1): 39-44.
96. Ligresti, A., Moriello, A.S., Starowicz, K. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006, 318(3): 1375-87.
97. McAllister, S.D., Christian, R.T., Horowitz, M.P., Garcia, A. and Desprez, P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007, 6(11): 2921-7.
98. Hart, S., Fischer, O.M. and Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004, 64(6): 1943-050.
99. McKallip, R.J., Nagarkatti, M. and Nagarkatti, P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the anti-tumor immune response. J Immunol 2005, 174(6): 3281-9.
100. O'Sullivan, S.E. Cannabinoids go nuclear: evidence for detivation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007, 152(5): 576-82.
101. Liu, J., Li, H., Burstein, S.H., Zurier, R.B. and Chen, J.D. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003, 63(5): 983-92.